Halozyme Therapeutics (HALO): Valuation Check After FDA Win and Patent Court Victory [Yahoo! Finance]
Halozyme Therapeutics (HALO) Is Up 7.4% After New ENHANZE NSCLC Win And Patent Injunction - What's Changed [Yahoo! Finance]
Is Halozyme Still Attractively Priced After Its Strong 2025 Share Price Rally? [Yahoo! Finance]
Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™' [Yahoo! Finance]
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.